The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for ...

But in the 1990s the virus that causes AIDS turned out to offer a solution. Researchers discovered how to strip away HIV’s destructive genes and repurpose it as a “lentiviral vector”—a tool to deliver ...

Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...

Radiation therapy has been a foundation of cancer care for more than a century. From early X-ray machines to today’s ...

The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.

AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...

Walmart’s addition follows its move last year to shift its stock listing from the New York Stock Exchange to Nasdaq, the ...

A phase 3 study of AstraZeneca’s ceralasertib has missed its primary endpoint, dealing another blow to efforts to use a synthetic lethal mechanism to overcome resistance to immuno-oncology drugs. The ...

Phase III trial involved 594 patients across 20 countries Ceralasertib-Imfinzi combo showed no new safety concerns AstraZeneca shares fall 1% after trial results Dec 22 (Reuters) - AstraZeneca (AZN.L) ...

Seven years after the FDA's accelerated approval of bleeding reversal agent Andexxa, which was then under the ownership of Portola Pharmaceuticals, the drug's round trip on the U.S. market is coming ...

For anyone wondering whether AstraZeneca is still worth considering after its big run or whether the best days are already priced in, this article will walk through what the numbers are really saying ...

Malawi Police Chief Luhanga promotes two officers over successful Lilongwe's Mbowe robbery stoppage - The Maravi Post ...